High susceptibility of human cancer Xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'- methylidenecytidine

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 493-497

  Miwa, Masanori ^a   Eda, Hiroyuki ^a   Ura, Masako ^a   Ouchi, Kaori F ^a   Keith, Dennis D ^b   Foley, Louise H ^b   Ishitsuka, Hideo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE; DNA POLYMERASE; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DEAMINATION; DRUG EFFICACY; ENZYME ACTIVITY; GENE TARGETING; GENETIC SUSCEPTIBILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DISEASE SUSCEPTIBILITY; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031913998     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Braakhuis, B. J. M., van Dongen, G. A. M. S., Vermorken, J. B., and Snow, G. B. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res., 51: 211-214, 1991.
2. Hertel, L. W., Boder, G. B., Stan Kroin, J., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluorodeoxycytidine). Cancer Res., 50: 4417-4422, 1990.
3. Wodinsky, I., and Kensler, C. J. Activity of 1-β-D-arabinofuranosylcytosine (NSC-63878) in a spectrum of rodent tumors. Cancer Chemother. Rep., 47: 65-68, 1965.
4. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
5. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
6. Heinemann, V., Xu, Y-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., and Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluoro-deoxycytidine. Mol. Pharmacol., 38: 567-572, 1990.
7. Carmichael, J., Fink, U., Russell, R. C. G., Spittle, M. F., Harris, A. L., Spiessi, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1996.
8. Gatzemeier, U., Shepherd, F. A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H. J. M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., Burkes, R. L., Gottfried, M., and Voi, M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur. J. Cancer, 32A: 243-248, 1996.
9. Possinger, K. Gemcitabine in advanced breast cancer. Anti-Cancer Drugs, 6 (Suppl. 6): 55-59, 1995.
10. Matsuda, A., Azuma, A., Nakajima, Y., Takenuki, K., Dan, A., Iino, T., Yoshimura, Y., Minakawa, N., Tanaka, M., and Sasaki, T. Design of new types of antitumor nucleosides: the synthesis and antitumor activity of 2′-deoxy-(2′-C-substituted) cytidines. In: C. K. Chu and D. C. Baker (eds.), Nucleosides and Nucleotides as Antitumor and Antiviral Agents, pp. 1-22. New York: Plenum Publishing Corp., 1993.
11. Baker, C. H., Banzon, J., Bollinger, J. M., Stubbe, J., Samano, V., Robins, M. J., Lippert, B., Jarvi, E., and Resvick, R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
12. Yamagami, K., Fujii, A., Arita, M., Okumoto, T., Sakata, S., Matsuda, A., Ueda, T., and Sasaki, T. Antitumor activity of 2′-deoxy-2′-methylidenecytidine, a new 2′-deoxycytidine derivative. Cancer Res., 51: 2319-2323, 1991.
13. Bouffard, D. Y., Laliberte, J., and Momparler, R. L. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol., 45: 1857-1861, 1993.
14. Takenuki, K., Matsuda, A., Ueda, T., Sasaki, T., Fujii, A., and Yamagami, K. Design, synthesis, and antineoplastic activity of 2′-deoxy-2′-methylidenecytidine. J. Med. Chem., 31: 1063-1064, 1988.
15. Maehara, Y., Nakamura, H., Nakane, Y., Kawai, K., Okamoto, M., Nagayama, S., Shirasaka, T., and Fujii, S. Activities of various enzymes of pyrimidine nucleotide and DNA synthesis in normal and neoplastic human tissues. Gann, 73: 289-298, 1982.
16. Chou, T. S., Heath, P. C., Patterson, L. E., Poteet, L. M., Lakin, R. E., and Hunt, A. H. Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its use in the preparation of 2′-deoxy-2′,2′-difluoro-β-D-ribofuranosyl pyrimidine nucleosides: the key role of selective crystallization. Synthesis, 565-570, 1992.
17. 3. Biochem. Biophys. Acta, 1312: 99-104, 1996.
18. Tamura, S., Fujimoto-Ouchi, K., Mori, K., Endo, M., Matsumoto, T., Eda, H., Tanaka, Y., Ishitsuka, H., Tokita, H., and Yamaguchi, K. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res., 1: 1353-1358, 1995.
19. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
20. Harkrader, R. J., Jackson, R. C., Ross, D. A., and Weber, G. Increase in liver and kidney deoxycytidine kinase activity linked to neoplastic transformation. Biochem. Biophys. Res. Commun., 96: 1633-1639, 1980.
21. Gandhi, V., and Plunkett, W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res., 50: 3675-3680, 1990.
22. Ruiz van Haperen, V. W. T., Veerman, G., Braakhuis, B. J. M., Vermorken, J. B., Boven, E., Leyva, A., and Peters, G. J. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumor xenografts. Eur. J. Cancer, 29A: 2132-2137, 1993.
23. Eda, H., Ura, M., Ouchi, K., Tanaka, Y., Miwa, M., and Ishitsuka, H. Modulation of the antiproliferative activity of 2′-deoxy-2′-methylidene cytidine (DMDC) by inhibiting cytidine deaminase activity and by gene transfection of the enzyme. Proc. Am. Assoc. Cancer Res., 38: 315, 1997.